Shaw J H, Humberstone D M, Wolfe R R
University Department of Surgery, Auckland Hospital, New Zealand.
Ann Surg. 1988 Mar;207(3):283-9. doi: 10.1097/00000658-198803000-00010.
We have performed a series of isotopic infusions both in normal volunteers (N = 16) and in sarcoma patients (N = 7). Using the primed-constant infusion of stable or radioisotopes we have determined the rates of glucose turnover, glucose oxidation, glucose recycling, and net protein catabolism (NPC). In addition, we have measured VO2 and VCO2. The values for VCO2 and VO2 were higher in the patients than in the volunteers (mean VO2 values in volunteers and patients: 107 +/- 13 and 158 +/- 13 mumol/kg/min, respectively). The basal rate of glucose appearance in the sarcoma patients was twice the value seen in the volunteers (28.3 +/- 3.5 vs. 13.9 +/- 0.3 mumol/kg/min). Glucose infusion in the volunteers resulted in virtually total suppression of endogenous glucose production, while in the patients glucose infusion induced only a 30% suppression of endogenous glucose production (p less than 0.01). The rate of glucose clearance in the patients was approximately twice the value seen in the volunteers [5.4 +/- 1.0 vs. 2.7 +/- 0.1 mL/kg/min (p less than 0.01)]. The per cent of glucose uptake oxidized in the patients was significantly less than in the volunteers [22% vs. 36% (p less than 0.05)], and the per cent of glucose uptake that was recycled was significantly higher in the patients [55% vs. 10% (p less than 0.01)]. In addition, the basal rate of net protein loss was increased twofold in the patients [3.2 +/- 0.5 vs. 1.4 +/- 0.4 g (protein)/kg/d (p less than 0.01)], and in contrast to the situation in the volunteers there was no suppression in the rate of net protein loss when the patients were infused with glucose. The basal insulin concentration and the insulin response to glucose infusion in the patients were similar to that of the volunteers, but the plasma cortisol level was similar in volunteers and in the patients (p less than 0.05). We conclude from these studies the following: (1) Sarcoma patients have significantly elevated rates of glucose production and glucose clearance, but they have an impaired capacity to directly oxidize either endogenous or infused glucose, coupled with an increased rate of glucose recycling. (2) Sarcoma patients have an elevated metabolic rate and are catabolic. In addition, in contrast with normal volunteers, glucose infusion does not result in a suppression of protein loss.
我们对16名正常志愿者和7名肉瘤患者进行了一系列同位素输注。通过使用稳定或放射性同位素的初始恒速输注,我们测定了葡萄糖周转率、葡萄糖氧化率、葡萄糖再循环率和净蛋白分解代谢率(NPC)。此外,我们还测量了VO2和VCO2。患者的VCO2和VO2值高于志愿者(志愿者和患者的平均VO2值分别为107±13和158±13μmol/kg/min)。肉瘤患者的基础葡萄糖出现率是志愿者的两倍(28.3±3.5对13.9±0.3μmol/kg/min)。在志愿者中输注葡萄糖几乎完全抑制了内源性葡萄糖的产生,而在患者中输注葡萄糖仅导致内源性葡萄糖产生抑制30%(p<0.01)。患者的葡萄糖清除率约为志愿者的两倍[5.4±1.0对2.7±0.1mL/kg/min(p<0.01)]。患者中被氧化的葡萄糖摄取百分比显著低于志愿者[22%对36%(p<0.05)],并且患者中被再循环的葡萄糖摄取百分比显著高于志愿者[55%对10%(p<0.01)]。此外,患者的基础净蛋白丢失率增加了两倍[3.2±0.5对1.4±0.4g(蛋白)/kg/d(p<0.01)],与志愿者的情况相反,当给患者输注葡萄糖时,净蛋白丢失率没有受到抑制。患者的基础胰岛素浓度和对葡萄糖输注的胰岛素反应与志愿者相似,但志愿者和患者的血浆皮质醇水平相似(p<0.05)。我们从这些研究中得出以下结论:(1)肉瘤患者的葡萄糖产生率和葡萄糖清除率显著升高,但他们直接氧化内源性或输注葡萄糖的能力受损,同时葡萄糖再循环率增加。(2)肉瘤患者的代谢率升高且处于分解代谢状态。此外,与正常志愿者不同,输注葡萄糖不会导致蛋白丢失受到抑制。